Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIOHM Probiotic in Breast Cancer
NCT04362826Recruiting
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Randomised, double-blind trial (2 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoints: Beta-D-Glucagon levels at 6 weeks, Short-chain fatty acid levels at 6 weeks and 1 more. Started Mar 2026; status: recruiting.
Beyond the preview
Go deeper on NCT04362826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04362826.